Patents Assigned to D.Western Therapeutics Institute
-
Patent number: 11534505Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.Type: GrantFiled: May 18, 2018Date of Patent: December 27, 2022Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Makoto Takahagi, Nobuhiro Haga, Atsushi Inoue
-
Patent number: 11535595Abstract: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.Type: GrantFiled: December 16, 2019Date of Patent: December 27, 2022Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo Sumi, Ryohei Nakamura
-
Patent number: 11427546Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.1°, 12.7±0.1°, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.1°, 25.5±0.1°, 25.8±0.1°, 29.8±0.1°, 39.5±0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.Type: GrantFiled: December 16, 2019Date of Patent: August 30, 2022Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Takashi Izuhara
-
Publication number: 20220017469Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.10, 12.7±0.10, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.10, 25.5±0.1°, 25.8±0.1°, 29.8-0.1°, 39.5-0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.Type: ApplicationFiled: December 16, 2019Publication date: January 20, 2022Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Hiroyoshi HIDAKA, Kengo SUMI, Takashi IZUHARA
-
Publication number: 20210395205Abstract: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.Type: ApplicationFiled: December 16, 2019Publication date: December 23, 2021Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo SUMI, Ryohei NAKAMURA
-
Publication number: 20210371396Abstract: A method may produce an isoquinoline-6-sulfonamide derivative useful as a medicinal drug; and an intermediate which is used for the method, and more specifically, a 1,4-diazocane compound of formula (8), wherein R4 is an amino protecting group, or a salt thereof.Type: ApplicationFiled: November 1, 2019Publication date: December 2, 2021Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo SUMI, Tomoyuki KOIDE, Osamu KIMATA, Yuji TAKASHIMA, Kazunao MASUBUCHI
-
Patent number: 8951997Abstract: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH?CH, O, or S; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.Type: GrantFiled: June 18, 2010Date of Patent: February 10, 2015Assignee: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kouichi Takahashi, Yoshihiro Inoue, Kengo Sumi, Ryohei Nakamura
-
Patent number: 8883792Abstract: The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R1 and R2 each independently represent a hydrogen atom, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like; R5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms.Type: GrantFiled: December 21, 2011Date of Patent: November 11, 2014Assignee: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Kouichi Takahashi, Yoshihiro Inoue
-
Publication number: 20130274269Abstract: The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R1 and R2 each independently represent a hydrogen atom, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like; R5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms.Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicant: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Kouichi Takahashi, Yoshihiro Inoue
-
Publication number: 20120035159Abstract: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH?CH, O, or S; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.Type: ApplicationFiled: June 18, 2010Publication date: February 9, 2012Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INCInventors: Hiroyoshi Hidaka, Kouichi Takahashi, Yoshihiro Inoue, Kengo Sumi, Ryohei Nakamura
-
Patent number: 7858615Abstract: The present invention is directed to (S)-(?)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate, to a method producing the dihydrate, and to a drug composition containing the dihydrate. The compound of the present invention has less hygroscopicity as compared with (S)-(?)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride anhydrous crystals and thus, exhibits excellent chemical stability.Type: GrantFiled: November 29, 2005Date of Patent: December 28, 2010Assignees: Kowa Co., Ltd., D. Western Therapeutics Institute, Inc.Inventors: Takeshi Ohshima, Hiroyoshi Hidaka, Masami Shiratsuchi, Kazuhiro Onogi, Toshiaki Oda
-
Publication number: 20080021018Abstract: The present invention is directed to (S)-(?)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate, to a method producing the dihydrate, and to a drug composition containing the dihydrate. The compound of the present invention has less hygroscopicity as compared with (S)-(?)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride anhydrous crystals and thus, exhibits excellent chemical stability.Type: ApplicationFiled: November 29, 2005Publication date: January 24, 2008Applicants: Kowa Co., Ltd, D. Western Therapeutics Institute, Inc.Inventors: Takeshi Ohshima, Hiroyoshi Hidaka, Masami Shiratsuchi, Kazuhiro Onogi, Toshiaki Oda
-
Publication number: 20060128762Abstract: The present invention provides an excellent method and a pharmaceutical composition for treating a malignant tumor, and use thereof. Specifically, the present invention is related to a pharmaceutical composition for treating malignant tumor comprising a specific aminostilbazole derivative or a pharmaceutically acceptable salt thereof, which is administered in combination with chemotherapy and/or radiotherapy, a method of treatment and use of said compound.Type: ApplicationFiled: September 5, 2003Publication date: June 15, 2006Applicants: D.Western Therapeutics Institute, NIPPON SHINYAKU CO.,Inventors: Hiroyoshi Hidaka, Masato Matsuda, Fumitake Katoh